Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Physostigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 14/20 | 0.98 |
| ▸ | BCHE | P06276 | 11/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Physostigmine SCHEMBL7587896 | 1.00 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL29482277 | 0.99 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL4104619 | 0.99 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24044 | 0.99 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL8800695 | 0.99 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL9988368 | 0.99 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24045 | 0.99 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL13930339 | 0.99 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| (+)-Physostigmine SCHEMBL15677750 | 0.99 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7581684 | 0.98 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061952-A2 | COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | MERCK SHARP & DOHME LTD. (GB) | 2000-12-27 | — | — | EP | claimed |
| WO-1999047131-A2 | COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | MERCK SHARP & DOHME LIMITED (GB) | 1999-09-23 | — | — | WO | claimed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-RE49647-E1 | Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | CELGENE CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230277539-A1 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX LLC (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX LLC (US) | 2023-08-03 | — | — | US | disclosed |
| EP-3660020-B1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2005065455-A1 | IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CELGENE CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065372-A2 | METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM DISORDERS OR DISEASES | CELGENE CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143344-A1 | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases | CELGENE CORPORATION | 2005-06-30 | — | — | US | disclosed |
| EP-1543157-A2 | METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY | PTC Therapeutics, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004080393-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040175382-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | CELGENE CORPORATION | 2004-09-09 | — | — | US | disclosed |
| WO-2004010106-A2 | METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004001010-A2 | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY | PTC THERAPEUTICS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2002099982-A2 | METHODS FOR IMPROVING SIGNAL DETECTION FROM AN ARRAY | ILLUMINA, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, IL15, CXCR5 | ACHE 4820/4885BCHE 4732/4885KDM4E 705/4885 |
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, HPGDS, EGLN2 | ACHE 3399/4885BCHE 3152/4885KDM4E 1112/4885 |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | ACHE 3218/4885BCHE 2930/4885KDM4E 2119/4885 |
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | HPGDS, HPGD, AQP3 | ACHE 3754/4885BCHE 2983/4885KDM4E 732/4885 |
| US-20050143344-A1 | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases | SMN1; SMN2, GBA1, AQP4 | ACHE 18/4885BCHE 32/4885KDM4E 3601/4885 |
| US-20230277539-A1 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | AQP3, AQP4, AQP1 | ACHE 3625/4885BCHE 4171/4885KDM4E 1210/4885 |
| US-20040175382-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | IL2, IL6, BDNF | ACHE 53/4885BCHE 106/4885KDM4E 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.